Atossa Therapeutics presents data from research investigating Z-Endoxifen

Atossa Therapeutics (ATOS) announced the presentation of research investigating the anti-cancer activity of (Z)-endoxifen and its byproducts at the American Association for Cancer Research, AACR, Special Conference in Cancer Research, taking place in Toronto from December 9-11. The poster, titled, “Anti-cancer activity of (Z)-endoxifen-related compounds in ERalpha+ breast cancer,” outlines results from a study investigating four (Z)-endoxifen byproducts for their anti-estrogenic and anti-tumor effects in estrogen receptor-positive breast cancer cell lines, including those with ESR1 mutations associated with endocrine resistance. Notably, compounds AT416E and AT402E demonstrated strong anti-proliferative activity, with AT416E also showing enhanced inhibition of cell migration and invasion. All four byproducts exhibited greater anti-proliferative effects than (Z)-endoxifen in estrogen-deficient conditions, while (Z)-endoxifen remained the most potent at inducing cell cycle arrest and apoptosis, reinforcing its potential as a therapeutic agent.